NuCana (NASDAQ:NCNA) Posts Quarterly Earnings Results, Beats Expectations By $1.66 EPS

NuCana (NASDAQ:NCNA) posted its earnings results on Thursday. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($2.65) by $1.66, Zacks reports.

NuCana Trading Up 7.4%

Shares of NCNA traded up $0.11 during mid-day trading on Friday, hitting $1.59. 70,877 shares of the company’s stock were exchanged, compared to its average volume of 34,591. NuCana has a fifty-two week low of $1.21 and a fifty-two week high of $7.22. The business’s 50 day moving average is $1.51 and its two-hundred day moving average is $1.87. The firm has a market capitalization of $6.62 million, a P/E ratio of -0.42 and a beta of 2.25.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.